Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB–IIIA non-small cell lung cancer (WJTOG0101)

医学 吉西他滨 内科学 危险系数 特加福 阶段(地层学) 临床终点 胃肠病学 肺癌 佐剂 肿瘤科 辅助治疗 不利影响 置信区间 外科 癌症 临床试验 生物 古生物学
作者
Masafumi Yamaguchi,Hirohito Tada,Tetsuya Mitsudomi,Takashi Seto,Kohei Yokoi,Nobuyuki Katakami,Kazuhiko Nakagawa,Makoto Oda,Mitsunori Ohta,Toshiyuki Sawa,Motohiro Yamashita,Norihiko Iked,Hideo Saka,Masahiko Higashiyama,Hiroaki Nomori,Hiroshi Semba,Shunichi Negoro,Yasutaka Chiba,Mototsugu Shimokawa,Masahiro Fukuoka,Yoichi Nakanishi
出处
期刊:International Journal of Clinical Oncology [Springer Science+Business Media]
卷期号:26 (12): 2216-2223 被引量:6
标识
DOI:10.1007/s10147-021-02012-9
摘要

Adjuvant oral uracil-tegafur (UFT) has led to significantly longer postoperative survival among patients with non-small-cell lung cancer (NSCLC). Gemcitabine (GEM) monotherapy is also reportedly effective for NSCLC and has minor adverse events (AEs). This study compared the efficacy of GEM- versus UFT-based adjuvant regimens in patients with completely resected pathological stage (p-stage) IB–IIIA NSCLC. Patients with completely resected p-stage IB–IIIA NSCLC were randomly assigned to GEM or UFT. The primary endpoint was overall survival (OS); secondary endpoints were disease-free survival (DFS), and AEs. We assigned 305 patients to the GEM group and 303 to the UFT group. Baseline factors were balanced between the arms. Of the 608 patients, 293 (48.1%) had p-stage IB disease, 195 (32.0%) had p-stage II disease and 121 (19.9%) had p-stage IIIA disease. AEs were generally mild in both groups, and only one death occurred, in the GEM group. After a median follow-up of 6.8 years, the two groups did not significantly differ in survival: 5 year OS rates were GEM: 70.0%, UFT: 68.8% (hazard ratio 0.948; 95% confidence interval 0.73–1.23; P = 0.69). Although GEM-based adjuvant therapy for patients with completely resected stage IB–IIIA NSCLC was associated with acceptable toxicity, it did not provide longer OS than did UFT.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
研友_VZG7GZ应助欣喜沛芹采纳,获得10
2秒前
感动黄豆完成签到,获得积分20
3秒前
4秒前
4秒前
6秒前
8秒前
Owen应助Kikua采纳,获得10
8秒前
juliar完成签到 ,获得积分10
8秒前
9秒前
Bressanone发布了新的文献求助10
9秒前
10秒前
彭于晏应助忐忑的阑香采纳,获得10
10秒前
赘婿应助xiaojian_291采纳,获得10
10秒前
11秒前
郭小宝发布了新的文献求助20
11秒前
糊涂的语兰完成签到,获得积分10
12秒前
浮生若梦完成签到 ,获得积分10
13秒前
CA发布了新的文献求助10
13秒前
忘记时间发布了新的文献求助30
13秒前
王羊补牢完成签到,获得积分10
15秒前
16秒前
潇湘雪月发布了新的文献求助10
21秒前
栗园应助仙都丽娜采纳,获得10
22秒前
严珍珍完成签到 ,获得积分10
22秒前
思源应助郭小宝采纳,获得10
22秒前
无理完成签到 ,获得积分10
23秒前
25秒前
25秒前
无端完成签到 ,获得积分20
25秒前
感动黄豆发布了新的文献求助10
26秒前
量子星尘发布了新的文献求助10
26秒前
27秒前
zwy109发布了新的文献求助10
28秒前
30秒前
立夏完成签到,获得积分10
31秒前
31秒前
32秒前
32秒前
33秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989242
求助须知:如何正确求助?哪些是违规求助? 3531393
关于积分的说明 11253753
捐赠科研通 3270010
什么是DOI,文献DOI怎么找? 1804868
邀请新用户注册赠送积分活动 882084
科研通“疑难数据库(出版商)”最低求助积分说明 809136